DSC
BBH icon

Duncker Streett & Co’s VanEck Biotech ETF BBH Stock Holding History

Duncker Streett & Co’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$331 – 479
2023
Q4 		$331 Buy
+2
New +$308 ﹤0.01% 478

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
CIG
Consolidated Investment Group Englewood, Colorado $1.15B AUM 55.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Duncker Streett & Co's BBH Position: Q1 2024 in Review

Duncker Streett & Co sold out of VanEck Biotech ETF (BBH) in Q1 2024, closing a stake of 2 shares — an estimated $331 sold.

Duncker Streett & Co first reported a position in BBH in Q4 2023 and held it in 1 quarter. The position peaked at $331 in Q4 2023. 113 funds tracked by Wall St. Rank hold BBH as of Q1 2024.

  • Duncker Streett & Co reported no remaining VanEck Biotech ETF position as of Q1 2024 after selling out during the quarter.
  • Duncker Streett & Co sold 2 VanEck Biotech ETF shares in Q1 2024, an estimated $331.
  • Duncker Streett & Co first reported a position in VanEck Biotech ETF in Q4 2023 and held it in 1 quarter.
  • Duncker Streett & Co's VanEck Biotech ETF position peaked at $331 in Q4 2023.
  • 113 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2024.

Based on Duncker Streett & Co's 13F filing for Q1 2024, filed 23 Apr 2024.